Oct 27, 2025
As the lupus treatment landscape undergoes major changes, Roche is entering the US lupus nephritis market with a fresh FDA approval for its long-standing blood cancer drug, GAZYVA. On October 20, 2025, Roche’s Genentech division announced that the FDA had approved GAZYVA (obinutuzumab) for use in adults with active...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper